Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1CNS 1

Conditions

Lymphoma 173Lymphoma, Non-Hodgkin 155Leukemia, Lymphocytic, Chronic, B-Cell 154Lymphoma, Large B-Cell, Diffuse 134Lymphoma, Follicular 131Lymphoma, Mantle-Cell 93Leukemia 68Lymphoma, B-Cell, Marginal Zone 67Waldenstrom Macroglobulinemia 49Burkitt Lymphoma 43Lymphoma, B-Cell 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Hodgkin Disease 36Recurrence 24Lymphoma, Large-Cell, Immunoblastic 24Neoplasms 15Myelodysplastic Syndromes 15Lymphoma, Large-Cell, Anaplastic 15Multiple Myeloma 13Leukemia, Myeloid, Acute 12Lymphoma, T-Cell, Cutaneous 9Lymphoma, Extranodal NK-T-Cell 9Leukemia, Hairy Cell 9Intraocular Lymphoma 9Hematologic Neoplasms 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Immunoblastic Lymphadenopathy 8Sezary Syndrome 7Mycosis Fungoides 7Lymphoma, T-Cell 7

Interventions

Radiotherapy 2Pyridoxine 2Etoposide 2Cytarabine 2Cyclophosphamide 2sodium thiosulfate 1pegfilgrastim 1pegaspargase 1etoposide phosphate 1Vincristine 1Triptorelin Pamoate 1Rituximab 1Prednisolone 1Methylprednisolone 1Methotrexate 1Mercaptopurine 1Leucovorin 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Doxorubicin 1Dexrazoxane 1Dexamethasone 1Celecoxib 1Carboplatin 1Capecitabine 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Drug-Related Side Effects and Adverse Reactions × Rituximab × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡